OECD Home › Science and technology › More News
More than 35 million people worldwide had dementia in 2010 and this number is expected to exceed 115 million by 2050. This paper reports on the opportunities offered by the informatics revolution and big data to address Alzheimer’s Disease and dementia. This will require careful planning and multi-stakeholder collaboration as technical, administrative, regulatory, infrastructure and financial obstacles emerge.
This report presents new evidence on how governments steer and fund public research in higher education and public research institutions through research excellence initiatives (REIs). It provides information on how REIs work and institutions that host centres of excellence. The findings show some of the benefits to be gained through REIs and pitfalls to be avoided.
An ageing population brings new challenges both to healthcare systems and to medicine in terms of the increased manifestation of specific diseases primarily seen in the elderly. Biomedical innovation, and in particular research into "omics technologies", offers the promise of new means of detection, prevention and treatment of age-related disabilities and diseases.
A timely set of indicators that reflect the level and structure of the efforts undertaken by OECD member countries and selected non-member economies in the field of science and technology.
OECD major events and activities relating to biotechnologies: latest developments are updated biannually in this Newsletter.
This report describes recent trends in government and institutional level policies to enhance the transfer and exploitation of public research. It also benchmarks a set of countries, universities and public research institutions based on both traditional and new indicators.
Dementia is a devastating condition for the people affected, their family and friends, and for health systems. Through its global reach and ability to bring together government and non-government perspectives, OECD is in a unique position to face up to the challenge.
As with every edition, the goal of the 2013 conference is to present the latest empirical evidence based on patent and IP statistics and to discuss these findings with decision-makers from both the private and public sectors. The conference also aims to share cutting-edge knowledge on topics relevant to policy-makers, academics, companies and practitioners.
Statistics on biotechnology firms, biotechnology R&D (including public sector expenditures), biotech applications and patents.
This paper explores the development of the bioplastics sector and its role in national bioeconomy strategies. It finds that bioplastics are at a disadvantage compared to some other biobased products, notably biofuels, that often benefit from preferential treatment. It also notes that greater efforts are needed at the international level as regards standards to avoid creating barriers to international trade in biobased products.